Profile: Seradyn, Inc. designs and manufactures therapeutic drug management (TDM), homogeneous immunoassays and microparticles. Our product area includes QMS® turbidimetric immunoassays, innofluor® fluorescence polarization immunoassays, particle technology, serology/slide agglutintion assays and antibodies/antigens. Our assays are designed for the monitoring of levels of therapeutic drugs in human serum or plasma. The concentrations of the drug can be used as an aid in the management of patients treated with that drug. Our QMS® turbidimetric immunoassays is a two component assay system that is based on the competitive inhibition immunoassay principle whereby free-drug in the sample competes for antibody binding sites with drug molecules coated onto uniform microparticles. The drug coated microparticle reagent is rapidly agglutinated in the presence of the antibody reagent and in the absence of any competing drug in the sample. The rate of absorbance change is measured photometrically and is proportional to the rate of agglutination of the microparticles. It is applicable to general chemistry analyzers. Our monoclonal antibodies include drugs of abuse, enzymes, hormones, immunoglobulins, antibodies for infectious diseases, serum proteins, antibodies for therapeutic drug monitoring, thyroids and tumor markers. Our recombinant antigens include rCEA, rCK-MB, rHBsAg and rTSH.

The company was founded in 1984, has revenues of USD 5-10 Million, has ~90 employees and is ISO 13485 certified. NASDAQ:APO (SEC Filings)